This inventor holds 9 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: The Wistar Institute, Active Biotech Ab, H. Lee Moffitt Cancer Center and Research Institute, Inc.. Active years: 2018-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
6 out of 246 
3 out of 43 
3 out of 312 
Years Active: 2018-2026
Title: The Innovative Contributions of Dmitry Gabrilovich
Introduction
Dmitry Gabrilovich is a prominent inventor based in Villanova, PA, known for his significant contributions to the field of cancer research. With a remarkable portfolio of 8 patents, his work primarily centers around innovative therapeutic methods and biological applications that aim to combat malignancies.
Latest Patents
Among his recent inventions, Gabrilovich has developed a variant survivin vaccine aimed at treating myeloma. This invention comprises a double mutant form of the survivin polypeptide, along with nucleic acid molecules that encode this variant. The technology involves antigen presenting cells such as dendritic cells, as well as methods for treating malignancies or inducing immune responses using the variant survivin polypeptide or nucleic acid sequences.
Another notable patent involves the use of lactoferrin for generating myeloid-derived suppressor cells (MDSCs) ex vivo, where blood cells are cultured with lactoferrin to enhance their effectiveness in immune suppression.
Career Highlights
Gabrilovich has played an integral role in advancing cancer therapies during his tenure at renowned institutions such as The Wistar Institute of Anatomy & Biology and the H. Lee Moffitt Cancer Center and Research Institute, Inc. His innovative spirit and dedication to research have made significant impacts in the understanding and treatment of cancer.
Collaborations
Throughout his career, Gabrilovich has collaborated with distinguished colleagues, including Frederick L. Locke and Scott Antonia. These partnerships have facilitated groundbreaking research and paved the way for novel therapeutic approaches in oncology.
Conclusion
Dmitry Gabrilovich exemplifies the essence of innovation in the field of cancer research. His patents and collaborative efforts have contributed to the development of new therapeutic strategies that hold promise for improving patient outcomes. As he continues to explore the frontiers of biological research, his work remains a vital part of the ongoing fight against cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile